Algorae Pharmaceuticals Ltd
Company Profile
Business description
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.
Contact
525 Collins Street
Level 23, Rialto South Tower
MelbourneVIC3000
AUST: +61 422180317
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
35
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,772.00 | 1.00 | -0.01% |
| CAC 40 | 7,662.59 | 3.32 | -0.04% |
| DAX 40 | 23,673.29 | 236.32 | -0.99% |
| Dow JONES (US) | 44,494.94 | 400.17 | 0.91% |
| FTSE 100 | 8,785.33 | 24.37 | 0.28% |
| HKSE | 24,072.28 | 211.87 | -0.87% |
| NASDAQ | 20,202.89 | 166.84 | -0.82% |
| Nikkei 225 | 39,986.33 | 501.06 | -1.24% |
| NZX 50 Index | 12,763.52 | 28.99 | 0.23% |
| S&P 500 | 6,198.01 | 6.94 | -0.11% |
| S&P/ASX 200 | 8,541.10 | 1.20 | -0.01% |
| SSE Composite Index | 3,444.43 | 20.20 | 0.59% |